Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder (DUART)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02891161 |
|
Recruitment Status : Unknown
Verified February 2021 by Monika Joshi, MD, Big Ten Cancer Research Consortium.
Recruitment status was: Active, not recruiting
First Posted : September 7, 2016
Last Update Posted : February 8, 2021
|
Sponsor:
Monika Joshi, MD
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Monika Joshi, MD, Big Ten Cancer Research Consortium
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet
publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending
Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during
QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review
assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific
validity or relevance of the submitted information.
| Recruitment Status : | Unknown |
|---|---|
| Estimated Primary Completion Date : | March 2021 |
| Estimated Study Completion Date : | March 2022 |
| Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
|---|---|---|
| 1 |
June 29, 2022 | July 28, 2022 |
| 2 |
September 29, 2022 | October 24, 2022 |
| 3 |
October 13, 2023 | November 7, 2023 |